A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". - Wikidata - awgldk - TriplyDB

A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers".

A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers".

http://www.wikidata.org/entity/Q30440347

about

Cancer classification using the Immunoscore: a worldwide task force Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology Response definition criteria for ELISPOT assays revisited Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program.Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force.Preamble to the 2015 SITC immunotherapy biomarkers taskforce SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery Newborn neurobehavioral patterns are differentially related to prenatal maternal major depressive disorder and serotonin reuptake inhibitor treatment Defining the critical hurdles in cancer immunotherapy.The immunologic aspects of poxvirus oncolytic therapy New take on comparative immunology: relevance to immunotherapy.Antitumor vaccines, immunotherapy and the immunological constant of rejection Immunotherapy of cancer in 2012.Immunotherapy for melanoma: current status and perspectives.Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer.Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.Dendritic cell subsets as vectors and targets for improved cancer therapy What is a biomarker? Research investments and lack of clinical integration necessitate a review of biomarker terminology and validation schema.New technologies for autoimmune disease monitoring Developing an effective breast cancer vaccine.Dendritic cells: are they clinically relevant?Monitoring cytokine profiles during immunotherapy.Immunological risk factors for infection after immunosuppressive and biologic therapies.Biomarkers in T cell therapy clinical trials.Multiplex serum biomarker assessments: technical and biostatistical issues.The immune score as a new possible approach for the classification of cancer.Translational Medicine is developing in China: a new venue for collaboration.Conference Scene: Immunotherapy reaches new milestones in cancer eradication.The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review.Pioneering the trail of cancer immunotherapy.Turning laboratory findings into therapy: a marathon goal that has to be reached.Molecular diagnostics in pancreatic cancer Melanoma & biomarkers of immunoresponsiveness

P2860

Q21245495-4E8B729F-05E8-4054-AE8C-23CE20A89041 Q30438965-C99CC012-D8A4-49D4-827B-491F5F6B89C0 Q30495664-715263F6-8AF2-4824-82E4-DD2EB6363F21 Q33619141-ED9B36FC-0384-409F-86BE-D0A1182F2C08 Q34461524-6A7AEF6C-189D-4ED9-81AB-251ED72B7AEB Q35212166-7DDF4146-E865-4099-92C8-02A6157DD16B Q35298744-2A4D8B00-E4AA-46DA-B5A7-F76E65C2B110 Q35549316-6C221EFD-924C-41F3-ACAC-92604EA62404 Q35916968-AA3A3F3D-4B0A-4D06-B321-3C14C2D417A3 Q36115128-2B4CDFDC-2446-4760-A848-3383FE2BFAA5 Q36126352-BB2E28BD-E162-4CFE-9DBE-C510CDADE724 Q36136498-EF32BA12-870F-4934-8FB8-C2402DEA1346 Q36243536-639BA004-AFF9-4A13-BCF1-806FF4ACC3FA Q36453216-BB2F76A8-1131-4B48-BD57-0F988EF75F9D Q36803441-2F484D4B-FDF4-4267-8F5A-18C13857C6E1 Q36958112-E95B38E4-85C9-4006-A513-4B64DE6AD80C Q37394755-16944381-C92D-4A59-80BB-1CB116FE592E Q37758502-8B02FAC2-3EA7-4C6D-8C18-F74E5DBF0D73 Q37761908-D6F535EA-5863-4C24-AC7D-6AD12EB75D28 Q37763474-AA821759-9BA4-4DF1-82A7-24FF8BDCD08A Q37776145-CA700BCB-50F0-4428-8EFC-28E55F2E4353 Q37778692-AEA929F6-BF3C-47C2-AFC0-8DC64421F22A Q37810959-DB8CA040-AEAC-4CDD-9AE2-A0E7F87BEED6 Q37866813-6DF1A142-2CD1-471A-8338-36E6FF551F0E Q37919589-CB02DF74-7A39-4065-9B7A-A35DAA8912B1 Q38806499-8DF79E68-4AC5-4A02-A16E-73A8827F2AD4 Q42539190-B4EC5F90-8F7E-4032-AB91-60C099F285A8 Q42575734-B4963331-E9D3-4B4E-B1EC-6AA53A8FAA4D Q45336492-9A401F72-E869-4B4B-A9DC-F2B24CA5148D Q49885285-7CF912BE-8744-4079-92DA-7A49906DEFA0 Q51160791-555E9A20-DD8B-474D-A6C3-047BB6B514B4 Q54956643-37D11C4D-6FA5-4C3A-A9E3-F2D8D36D2C43 Q57422493-1157EB7B-6E3B-4610-9197-E1C817DA7B11 Q58234468-13BD9A6D-1A31-4318-854D-DF623BD09BCB

P2860

A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers".

http://www.wikidata.org/entity/Q30440347

description

2008 nî lūn-bûn

@nan

2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

A systematic approach to bioma ...... on immunotherapy biomarkers".

@ast

A systematic approach to bioma ...... on immunotherapy biomarkers".

@en

type

label

A systematic approach to bioma ...... on immunotherapy biomarkers".

@ast

A systematic approach to bioma ...... on immunotherapy biomarkers".

@en

prefLabel

A systematic approach to bioma ...... on immunotherapy biomarkers".

@ast

A systematic approach to bioma ...... on immunotherapy biomarkers".

@en

P1433

Q30440347-B8E98D11-A132-4B2B-ACE7-B668DECF20B7

P1476

Q30440347-1F5D4D58-AE1E-4505-9A4F-5558DA226259

P2093

Q30440347-00E1E198-58F5-4A15-AAB9-19CF97A9F1AC

Q30440347-1979A7DB-CE78-4FAD-A9B3-8ABD2EE9D649

Q30440347-23B0EA7D-2733-4E5A-8DC8-99F20B5DA64D

Q30440347-28F03F16-127B-4663-9524-EDF36AA28003

Q30440347-2DB7AC67-5749-41B8-9A28-E9C10E19F111

Q30440347-2FDE0854-EF0A-4217-B2BA-D0B8DE8BC4F0

Q30440347-3305F0D4-303D-438C-B99F-6864CD8594E4

Q30440347-33C28D33-4E1A-4F6B-8CBC-F00D6619BB4B

Q30440347-4156272E-30C3-49EC-B9C7-942398F8045C

Q30440347-44B55153-93DA-4AD8-973A-146101A2331C

P2860

Q30440347-058A2B24-9D9A-479C-B6E8-2E4C5010789F

Q30440347-0BE4C2B9-4C4E-41C2-B0D1-E80873B72DD3

Q30440347-27505B07-C880-4436-8066-6BDF8C04FB4B

Q30440347-2A9D19FB-6334-4873-8366-DE67CD6560A2

Q30440347-460B6FBA-A3FD-451A-9F76-BD6AA0594B38

Q30440347-4B2E1BC4-40D5-464E-9AF2-99B412017479

Q30440347-4CA8937A-8506-4CA2-BFD6-0917E09F3459

Q30440347-4CAC0971-6E91-4B22-AA97-32DB60F49D39

Q30440347-4CEDD449-DEFA-4589-81B2-52B540A92E7E

Q30440347-59E40AC5-073B-4618-9645-47AC7D944D72

P2888

Q30440347-6F16DC4C-EFEC-462F-8614-035B5A663359

P304

Q30440347-194B1EFD-0E6F-42CE-8B35-056D6F8FD105

P31

Q30440347-0A8D4274-DADB-453C-AF1B-C12351E85623

Q30440347-2ec894b1-f889-4f99-a53a-14e3ff187fdb

P356

Q30440347-251A1287-6EBD-4D3A-A180-525FEBEBD865

P478

Q30440347-520C7786-ADF5-448F-8A5D-AD73EEABB5DE

P50

Q30440347-19FFE7FA-2F2C-4446-85BA-3913801FF173

Q30440347-33FF25E9-38BB-4D9C-A96E-1F3BA7C32C3E

Q30440347-35734CEF-85AD-47C1-AB47-E6A23CD3A049

Q30440347-96531FCD-86E7-40BA-91A5-E963BE95B155

Q30440347-C04B672E-4E2F-465D-BD27-136B29583260

Q30440347-CFCEF3A1-59BC-42B7-846A-8C208E94C0DD

Q30440347-D46F18E2-5E57-45C6-AC95-DBD68156E831

Q30440347-ECC0FF59-C714-4594-8E18-3F34FFABE294

P577

Q30440347-6D47FE4D-F958-4E95-A65E-3984A658018E

P5875

Q30440347-2443399D-F268-4B74-A85E-4441FC0D6ACF

P6179

Q30440347-8FB0C607-CB02-4245-8F35-2DD422DF8F51

P698

Q30440347-85AE7ED8-D1C1-4007-8FC0-9DEA794501C5

P921

Q30440347-2BF24050-E04C-4A7C-9691-E2853010A168

Q30440347-EFF0897A-51E5-46F8-8DE1-E99D7ED9B674

P932

Q30440347-31701FD5-CB9A-420B-BCBD-5D4777EEA152

P356

P1433

Journal of Translational Medicine

P1476

A systematic approach to bioma ...... on immunotherapy biomarkers".

@en

P2093

A Karolina Palucka

http://www.w3.org/2001/XMLSchema#string

Anatoli Malyguine

http://www.w3.org/2001/XMLSchema#string

Barbara Seliger

http://www.w3.org/2001/XMLSchema#string

Benjamin Zeskind

http://www.w3.org/2001/XMLSchema#string

Bernard A Fox

http://www.w3.org/2001/XMLSchema#string

Cristina Maccalli

http://www.w3.org/2001/XMLSchema#string

David F Stroncek

http://www.w3.org/2001/XMLSchema#string

Dolores Schendel

http://www.w3.org/2001/XMLSchema#string

Douglas M Potter

http://www.w3.org/2001/XMLSchema#string

Ena Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China

Melanoma-restricted genes

Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration

Selection and validation of endogenous reference genes using a high throughput approach

Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT

Detection of human MCP-4/CCL13 isoforms by SELDI immunoaffinity capture.

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)

Miniaturized, ultra-high throughput screening of tyrosine kinases using homogeneous, competitive fluorescence immunoassays.

P2888

P304

81

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1479-5876-6-81

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Licia Rivoltini

Lisa H. Butterfield

Giuseppe V Masucci

Damien Chaussabel

Craig Slingluff

P577

2008-12-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23687525

http://www.w3.org/2001/XMLSchema#string

P6179

1015694746

http://www.w3.org/2001/XMLSchema#string

P698

19105846

http://www.w3.org/2001/XMLSchema#string

P921

P932

2630944

http://www.w3.org/2001/XMLSchema#string